Business Context and Reporting Period
This Form 8-K Current Report was filed by Amneal Pharmaceuticals, Inc. on March 11, 2020. The filing discloses a significant executive leadership change within the company's finance department.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on executive compensation and appointment details.
Material Changes
Executive Transition: The Board of Directors appointed Anastasios (Tasos) G. Konidaris as Senior Vice President and Chief Financial Officer, effective March 12, 2020. He succeeds Todd P. Branning, who ceased serving as CFO effective March 11, 2020. Mr. Branning remains available to the company through March 31, 2020.
Reason for Change: The company explicitly states the transition is unrelated to the company's financial condition, operational performance, financial reporting, accounting practices, investments, policies, or regulatory condition.
Management Commentary and Compensation Details
The filing details the employment agreement entered into with Mr. Konidaris:
- Base Salary: $550,000 annually.
- Annual Bonus: Target of 55% of base salary, with a range of 0% to 150%.
- Long-Term Incentives: Grants of restricted stock units (RSUs) and performance-based RSUs, each with a grant date fair value of $1,000,000 (total $2,000,000).
- Severance: In the event of termination without cause or for good reason, the executive is entitled to 150% of annual base salary, a pro-rated bonus, 18 months of benefits continuation, and 12 months of outplacement assistance.
- Change in Control: Includes acceleration of equity vesting and exercisability if termination occurs within specific windows surrounding a change in control.
Investor Verification Checklist
- Verify the effective date of the CFO transition (March 12, 2020) and the interim coverage period provided by the outgoing CFO.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Confirm the vesting schedule and performance conditions for the $2,000,000 in equity awards.
- Monitor subsequent filings for any impact on financial reporting or operational strategy following the leadership change.